Dataset Information

Short Stature is Associated with Increased Risk of Dyslipidemia in Korean Adolescents and Adults.

ABSTRACT: Adults with short stature have been previously reported to have increased risk of cardiovascular events and hyper-LDL-cholesterolemia. We aimed to assess the association between height and lipid profiles among Korean adolescents and adults. We analyzed data from the Korea National Health and Nutrition Examination Survey from 2007 to 2015, from 37,889 individuals (aged 12-59 years). In adolescents, total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C) levels had profound associations with height in both boys and girls, while high density lipoprotein-cholesterol (HDL-C) levels had an inverse association with height only in boys. Height was inversely associated with TC, triglycerides (TG), and LDL-C concentrations in men and women and positively correlated with HDL-C concentration in women. In boys, the odds ratios (ORs) for hypercholesterolemia, hypertriglyceridemia, hyper-LDL-cholesterolemia were higher for shorter subjects (ORs = 2.38~7.01), while only the OR of hyper-LDL-cholesterolemia was significantly higher in girls with short stature (OR = 3.12). In adults, the ORs for hypercholesterolemia, hypo-HDL-cholesterolemia, and hyper-LDL-cholesterolemia were significantly higher in short subjects than in tall subjects after controlling for covariates (ORs = 1.50~2.61). Also, short men showed significantly higher ORs for hypertriglyceridemia (OR = 1.85) than tall men. Short stature was significantly associated with adverse lipid profiles in both adolescents and adults.

SUBMITTER: Oh NK

PROVIDER: S-EPMC6773853 | biostudies-other | 2019 Oct

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Short Stature is Associated with Increased Risk of Dyslipidemia in Korean Adolescents and Adults.

Oh Na-Kyung NK Song Yun-Mi YM Kim Shin-Hye SH Park Mi Jung MJ

Scientific reports 20191001 1

Adults with short stature have been previously reported to have increased risk of cardiovascular events and hyper-LDL-cholesterolemia. We aimed to assess the association between height and lipid profiles among Korean adolescents and adults. We analyzed data from the Korea National Health and Nutrition Examination Survey from 2007 to 2015, from 37,889 individuals (aged 12-59 years). In adolescents, total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C) levels had profound associat ...[more]

PMID: 31575921

Similar Datasets

Project description:Background:According to several studies, the autoimmune response may lead to osteoarthritis and dyslipidemia and may affect the homeostasis of the human body's internal environment and then cause its own immune regulation. Consequently, the risk of osteoarthritis might be increased by dyslipidemia, but this association is not universally acknowledged. Therefore, a systematic review and meta-analysis was conducted to study the relationship between dyslipidemia and the risk of osteoarthritis. Methods:In this study, PubMed, EMBASE, and the ISI Web of Science were used to identify related studies published before July 2018. The relationship between dyslipidemia and the risk of osteoarthritis was evaluated on the basis of relative risk (RR) values and the corresponding 95% confidence intervals (CIs). To further investigate this relationship, we also employed the random effects model proposed by DerSimonian and Laird. Results:A total of nine studies were included to study the effect of dyslipidemia on the risk of osteoarthritis, including four cohort, three case-control, and two cross-sectional studies. Among these studies, six stated data for knee osteoarthritis, two reported on hand osteoarthritis, and one reported on hip osteoarthritis. A total of 53,955 participants were included in the meta-analysis, comprising 22,501 patients with OA (19,733 hand OA, 2,679 knee OA, and 89 hip OA). Based on the meta-analysis of case-control and cross-sectional studies, osteoarthritis was clearly higher in those with dyslipidemia compared to those who did not suffer from dyslipidemia (case-control: OR = 1.37; 95%CI = 1.27-1.46; cross-sectional: OR = 1.33; 95%CI = 1.21-1.46). In addition, the meta-analysis of cohort studies did not present any relationship between dyslipidemia and OA (RR = 1.00; 95%CI = 0.85-1.14). Conclusions:Even though our meta-analysis of case-control and cross-sectional studies suggested a strong relationship between dyslipidemia and osteoarthritis; this relationship was not validated by our meta-analysis of only cohort studies. As a result, further investigation needs to be conducted on the relationship between dyslipidemia and osteoarthritis, considering the significant public health relevance of the topic.

Project description:BackgroundAs a result of the essential role of oestrogens in epiphyseal closure, aromatase inhibitors have been trialled as an intervention to improve height outcomes in male children and adolescents by inhibiting the conversion of testosterone to oestradiol.ObjectivesTo assess the effects of aromatase inhibitors in male children and adolescents with short stature.Search methodsTo identify relevant trials, we searched the Cochrane Library (2014, Issue 7), MEDLINE, EMBASE, and the World Health Organization (WHO) ICTRP trial register from their inception until August 2014. In addition, we conducted citation searches and screened reference lists of included trials.Selection criteriaWe included randomised controlled trials (RCTs) if they compared use of an aromatase inhibitor with placebo in male children and adolescents with short stature.Data collection and analysisTwo authors independently screened titles and abstracts for relevance. Both authors carried out screening for inclusion, data extraction, and risk of bias assessment, with any disagreements resolved following discussion. We assessed trials for quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) instrument. We contacted study authors regarding missing information. Primary outcomes were final or near-final height, adverse events, and health-related quality of life. Secondary outcomes included all-cause mortality, cognitive outcomes, socioeconomic effects, laboratory measures, short-term growth parameters, and assessment of effects on bone health. Meta-analysis was not appropriate due to the substantial clinical heterogeneity between trials; we presented the findings of the review in narrative format.Main resultsWe included four RCTs involving 207 participants (84 on interventions) in the review. Trials included males with constitutional delay of growth and puberty (CDGP), idiopathic short stature (ISS), and growth hormone (GH) deficiency. Three of the trials had an overall low or unclear risk of bias for primary outcomes. Short-term growth outcomes, such as predicted adult height, improved in all trials. Just one trial reported the primary outcome of final and near-final height as an extension under non-randomised conditions. None of the trials assessed health-related quality of life. One publication provided detailed information regarding the incidence of adverse events. A significant proportion (45%) of prepubertal boys with ISS treated with letrozole developed mild morphological abnormalities of their vertebrae, compared with none in the placebo group.Authors' conclusionsAvailable evidence suggested that aromatase inhibitors improved short-term growth outcomes. There was no evidence to support an increase in final adult height, based on limited data, with only one of four trials publishing final height data under non-randomised conditions.

Project description:ObjectivesDyslipidemia increases the risk of serious cardiovascular disease; and conventional cigarette smoking is widely recognized as a risk factor. Thus, as electronic cigarettes were introduced, many smokers utilized them for smoking cessation. However, due to the lack of researches scrutinized the relationship between dual smoking and dyslipidemia, a lot of those who failed in cessation end up utilizing both types of cigarettes (dual smoking). Therefore, this study aimed to examine the effect of dual smoking on dyslipidemia in South Korean adults.MethodsData were included from the 2013, 2014, 2015, 2016, and 2019 Korean National Health and Nutrition Examination Survey of 8,398 Korean men. The KNHANES is conducted by a national institution based on random cluster sampling, and therefore, the data gained from it is statistically reliable and representative in comparison to surveys performed by private institutions. Cigarette use status was the main independent variable. Cigarette use status was categorized as one of the four status: dual smoker, single smoker, non-smoker, and ex-smoker. The dependent variable, presence of dyslipidemia, was defined according to the National Cholesterol Education Program as displaying one or more of the following criteria: total cholesterol: ≥240 ㎎/dL, LDL cholesterol: ≥160 ㎎/dL, triglyceride: ≥200 ㎎/dL, or HDL cholesterol: ≤40 ㎎/dL. Multiple logistic regression analysis was performed to examine target association.ResultsCurrent and former users of either electronic or conventional cigarettes presented with a higher odd ratio of dyslipidemia compared to non-smokers. (ex-smoker: OR = 1.60, 95% CI = 1.41-1.83; single smoker: OR = 1.21, 95% CI = 1.06-1.38). More importantly, those who smoke both conventional and electronic cigarettes were also, at high risk of dyslipidemia (dual smoker: OR = 1.66, 95% CI = 1.26-2.20). Along with smoking status, those who did not exercise had a higher risk of dyslipidemia than those who exercised regularly and higher self-reported health status was also related to a lower risk of dyslipidemia.ConclusionThis study suggests that along with conventional cigarettes, dual smoking negatively impacts dyslipidemia, and smoking cessation of evert types is necessary for a healthy life.

Dataset Information

Short Stature is Associated with Increased Risk of Dyslipidemia in Korean Adolescents and Adults.

Publications

Short Stature is Associated with Increased Risk of Dyslipidemia in Korean Adolescents and Adults.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets